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ABSTRACT
Objective: The objective of the selective EBM review is to determine whether or not “Is
radiofrequency ablation effective in treating Barrett’s esophagus patients with high-grade
dysplasia?”
Study Design: Review of two randomized controlled trials and one cohort study. All three
studies were published in English in peer-reviewed journals after 2000.
Data Sources: Two randomized controlled trials and one cohort study found via PubMed.
Outcome(s) Measured: All three studies measured eradication of dysplasia via biopsy
evaluation. Other outcomes measured included progression to high-grade dysplasia or
adenocarcinoma based on histology findings, overall cancer risk based on observations of
patients in the registry, and rate of serious adverse events determined by any event that led to
death or required hospitalization.
Results: Phoa et. al and Haidry et. al found that RFA treatment was successful in treating
dysplastic Barrett’s esophagus. Though Shaheen et. al found that RFA treatment was successful
in eradication of dysplasia, given the poor study design and lack of control group, it cannot be
concluded whether or not RFA treatment was successful for patients with high-grade dysplasia.
Conclusions: Based on the results of the Haidry and Phoa studies, RFA was shown to be an
successful and cost-effective treatment method for the eradication of dysplastic Barrett’s
esophagus. The Shaheen study found that RFA was effective, however it is difficult to assess
validity of the data due to lack of a control group throughout the entirety of the study.
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INTRODUCTION
Barrett’s esophagus (BE) is “the replacement of normal esophageal squamous mucosa by
specialized intestinal columnar mucosa,” a complication of longstanding gastroesophageal reflux
disease (GERD) that is seen in about 10 to 15% of patients, increasing patients’ risk of
developing esophageal adenocarcinoma.4,10 Some patients with Barrett’s esophagus may develop
dysplasia, a precancerous change in the lining of the esophagus - though risk of developing
cancer is low at just “0.5 percent per year.”10 This paper evaluates two randomized controlled
trials (RCTs) and one cohort study evaluating the efficacy of radiofrequency ablation (RFA) as a
method of eradicating high-grade dysplasia in patients with Barrett’s esophagus.
The prevalence of Barrett’s esophagus is about 1.6% of the general population.8 In the
United States, adenocarcinoma of the esophagus is becoming more prevalent and is most often
seen in obese, Caucasian males, with a history of GERD.10 Though both photodynamic therapy
(PDT) and RFA are successful in treating dysplastic BE, success rates of eradication are higher
with RFA and “five times less costly than PDT.”1 RFA treatment course involves 2 to 3 sessions
1 to 4 times per year, with an average of 2 to 4 days of missed work per session. Given its short
recovery time, it is a cost-effective option for the treatment of dysplasia.5
Though the exact cause of Barrett’s esophagus is unknown, history of longstanding
GERD increases the risk of developing the condition.10 When a patient is diagnosed with
Barrett’s esophagus, a periodic endoscopy is the next step in management of this condition. If the
endoscopy does not show evidence of dysplasia, it should be repeated approximately every three
years.10 Typically first line treatment begins with high dose proton pump inhibitors or histamine
blockers.9 For high-grade dysplasia or cancer, esophagectomy is an option.2
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Once Barrett’s esophagus progresses to some form of dysplasia, more serious measures
must be taken to prevent further advancement to adenocarcinoma of the esophagus. One such
measure is RFA, which compared to PDT has a smaller side effect profile and costs less. In
addition, RFA can be controlled to a specified depth.1
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is
radiofrequency ablation effective in treating Barrett’s esophagus patients with high-grade
dysplasia?”
METHODS
This review focuses on patients over the age of 18 with Barrett’s esophagus and
endoscopic evidence of dysplasia, where all studies focus on RFA as the primary intervention.
Shaheen et. al focus on RFA compared to a sham endoscopic procedure.7 Haidry et. al focus on
RFA and endoscopic mucosal resection in a cohort study.3 Phoa et. al focus on RFA compared to
endoscopic surveillance (high-resolution endoscopy).6 Many outcomes are measured including
progression to high-grade dysplasia or adenocarcinoma, eradication of dysplasia, durability of
response, adverse reactions, and overall cancer risk. Two of the studies are RCTs and one is a
cohort study. All articles are published in English and in peer-reviewed journals found via
Pubmed using keyword searches such as “Barrett’s esophagus”, “radiofrequency ablation,” and
“dysplasia.” Inclusion criteria include articles published after the year 2000. Exclusion criteria
include patients under the age of 18 and history of malignancy. All articles are selected based on
relevance to the clinical question and inclusion of patient oriented outcomes (POEMs). Statistical
analysis is reported using Cox proportion hazard models, t tests, Kaplan-Meier survival curves,
χ2 tests, Fisher’s exact test, p value, NNT, and SD.3,6,7
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Table 1 – demographics and characteristics of included studies
Study
Type # Pts
Inclusion Criteria
Exclusion Criteria
Haidry
Cohort 920 Men and nonPregnant women,
(2015)3
pregnant women over contraindications to
the age of 21 years
endoscopy, <21 years
with no
of age.
contraindications to
endoscopy.
Phoa
RCT
136
Prior endoscopic
6
(2014)
treatment for Barrett
esophagus; history of
high-grade dysplasia
or adenocarcinoma;
active secondary
malignancy; estimated
life expectancy less
than 2 years; age of 18
years or younger or 85
years and older.
Shaheen RCT
127 Endoscopically
Pregnancy; active
7
(2011)
evident, non-nodular, esophagitis or
dysplastic BE <8cm
stricture; history of
in length; 18-80 y/o;
esophageal
for subjects with
malignancy, varices,
HGD, additional
uncontrolled
requirement of
coagulopathy, or life
endoscopic US
expectancy of <2
negative for
years, as judged by the
lymphadenopathy or
investigator.
esophageal wall
abnormalities within
12 months of
enrollment; previous
EMR permissible >8
weeks before entry,
provided that
subsequent
endoscopy
demonstrated nonnodular dysplasia.

W/D
Interventions
412 Radiofrequency
ablation and
endoscopic
mucosal
resection
7

Radiofrequency
ablation

10

Radiofrequency
ablation
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OUTCOMES MEASURED
Outcomes measured are those that focus on patient oriented evidence that matters
(POEM). All three studies measure eradication of dysplasia via biopsy evaluation.3,6,7 Other
outcomes measured include progression to high-grade dysplasia or adenocarcinoma based on
histology findings, overall cancer risk based on observations of patients within the registry, and
rate of serious adverse events determined by any event that led to death or required
hospitalization.3,6,7
RESULTS
This review examines two RCTs and one cohort study that evaluate RFA as a method of
eradication of dysplasia in Barrett’s esophagus patients. The results of the two RCTs are reported
as dichotomous data, so numbers needed to treat (NNT), relative benefit increase (RBI), and
absolute benefit increase (ABI) are calculated. The results from the cohort study cannot be
converted to dichotomous data.
In the Shaheen study, 127 subjects were divided into either a low-grade dysplasia (LGD)
or a high-grade dysplasia (HGD) group.7 Inclusion and exclusion criteria can be found in Table
1. Subjects were then randomized to receive either the sham endoscopic procedure (SHAM) or
the RFA treatment. Subjects in the experimental group received up to 4 RFA treatments at 0, 2,
4, and 9 months based on results from the biopsies, and 1 treatment in the second year. After one
year, 117 of the subjects completed follow up and 35 of the 39 subjects in the SHAM group were
“eligible for cross-over to the RFA treatment.”7 The remaining 4 participants developed
esophageal adenocarcinoma and were no longer eligible for crossover treatment. In the second
trial, 119 subjects underwent RFA, and 106 subjects made it to the 2-year follow up. The
primary outcome measured was whether or not complete eradication of dysplasia could be
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achieved. After 2 years, 51/52 (98%) subjects with low-grade dysplasia achieved complete
eradication and 50/54 (95%) subjects with high-grade dysplasia achieved complete eradication.
The results from the study can be found in Table 2.
Due to the crossover treatment option after one year, there was no longer a control group
at the end of the study. Therefore, values in Table 2 were calculated using the low-grade
dysplasia group as the control and the high-grade dysplasia group as the experimental group.
NNT was calculated to be -33, meaning for every 33 patients treated with RFA, one fewer would
achieve complete eradication of high-grade dysplasia. Given the poor study design, it is difficult
to assess whether or not RFA treatment was successful in eradication of high-grade dysplasia, as
there was no control group at the end of the study and therefore no reported p value. Upper
gastrointestinal hemorrhage and chest discomfort with nausea were the most common adverse
events noted after the study. No “procedure-related” deaths occurred.7
Table 2. Treatment Effects
STUDY
CER
Shaheen7
.98
Phoa6
.279

EER
.95
.926

RBI
-0.031
2.32

ABI
-0.03
.647

NNT
-33
1.545

In the Phoa study, 140 subjects were randomized to either the experimental group, where
they received RFA, or the control group, for endoscopic surveillance.6 Patients in the
experimental group were treated with either a circumferential or a focal device based on the
degree of their disease. RFA sessions were scheduled every 3 months until there was complete
eradication of dysplasia. Follow up endoscopy was 3 months after the last therapy session, where
biopsy samples were taken. The experimental group also received “double-dose proton pump
inhibition as maintenance therapy.”6 Patients in the control group “underwent high-resolution
endoscopy.”6 One subject in the RFA group progressed to adenocarcinoma and was treated with
endoscopic resection. This study found that RFA treatment was successful in treating BE
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dysplasia, with a statistically significant p value <0.001. Results from the study can be found in
Table 3. Esophageal stricture, bleeding, mucosal laceration, and abdominal pain were the noted
adverse events.6
Table 3. Complete Eradication of Dysplasia
STUDY
P-VALUE
OR
3
Haidry
P <0.0001
1.103
6
Phoa
P <0.001
N/A

95% CI
1.023 to 1.190
59.4-81.6%

RR
N/A
90%

In the Haidry cohort study, 920 patients within the UK registry were referred for
treatment – 508 completed treatment.3 RFA was completed with either a circumferential or with
several focal devices for shorter segments of Barrett’s esophagus. Patients received an average of
2 to 3 RFA treatments. At the end of protocol, patients without dysplasia were followed every 3
months for post-RFA surveillance during the first year, every 6 months for the following year,
and then annually after that. From 2008-2010, 206/266 (77%) of all patients achieved complete
eradication of dysplasia at the end of protocol.3 From 2011-2013, 222/242 (92%) of all patients
achieved complete eradication of dysplasia at the end of protocol.3 From 2008-2010 and then
from 2011-2013, 76% and 92% of patients with high-grade dysplasia (HGD) achieved complete
eradication respectively.3 These results were statistically significant, as the p value was less than
0.0001. Results can be found in Table 3.
DISCUSSION
Radiofrequency ablation is an “endoscopic technique in which diseased tissue is exposed
to heat energy and destroyed.”2 RFA is generally used as a treatment for Barrett’s esophagus.
The procedure lasts about 25-50 minutes and on average, patients have anywhere from 2 to 3.5
treatments. Commonly after treatment, patients complain about “chest discomfort, sore throat
and/or painful or difficult swallowing after the procedure.”5 Although RFA is considered a
generally safe procedure, and complications are seen in <1% of patients, there is always a
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possible risk of esophageal stricture, bleeding, infection, and death.2,5 Eradication rates range
from 72-100%.5
CONCLUSION
After careful review of these three studies, there is evidence in both the Phoa and Haidry
studies to suggest that radiofrequency ablation is a safe and effective treatment for patients with
endoscopic evidence of Barrett’s esophagus with dysplasia. Future research, however, is
warranted and should focus more on patients with high-grade dysplasia. Although the subjects in
the Shaheen study did see improvement in their dysplasia after the RFA treatments, due to the
poor study design and lack of control group at the end of the study, it is difficult to conclude
whether or not RFA was an effective treatment for patients with high-grade dysplasia. Compared
to other therapies, including PDT, RFA has a smaller side effect profile and costs less.1 The
studies each maintained appropriate follow up time with the subjects.
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